Navigation Links
Amylin Pharmaceuticals Reports First Quarter Financial Results
Date:4/18/2011

pected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results, may not be predictive of real world use or may not achieve desired end-points; risks that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion or that the BLA will not receive regulatory approval; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates, such as the BYDUREON NDA, or sNDAs for label expansion requests, may not be submitted timely or receive FDA approval; risks that BYDUREON will not be approved in the European Union; risks that the tQT study mentioned in this press release will not be completed in a timely manner; risks that our response to the FDA's BYDUREON complete response letter may not be submitted in a timely manner and/or the information we provide in our response may not satisfy the FDA; risks that the FDA may request additional information prior to approving BYDUREON; risks that our expense reductions will not be as large as we expect; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA or SYMLIN. These and additional risks and uncertainties are described more fully in the Company's recently filed Form 10-K. Amylin disclaims any obligation to update these forward-looking statements.(Financial information to follow)AMYLIN PHARMACEUTICALS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(unaudited)Quarter ended March 31, 20112010Revenues:  Net product sales

$150,8
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
2. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
3. Amylin Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
4. Amylin Pharmaceuticals to Present at the 2011 ISI Annual Conference
5. Amylin Pharmaceuticals Reports 2010 Financial Results
6. Amylin Pharmaceuticals to Webcast Year-End Financial Results
7. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Amylin Pharmaceuticals to Present at the 2010 Credit Suisse Healthcare Conference
11. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
(Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Remedy Informatics, the leading provider of integrated research management ... its Founder and CEO, Gary Kennedy, will participate as ... Management Track on Tuesday, Feb. 21, and as an ... TRI-CON Feb. 19-23, 2012, in San Francisco, Calif. ( ...
... ECRI Institute ®, an independent nonprofit organization that ... released CT Scanning Systems , a new "infographic-style ... overview of the current landscape of computed tomography (CT), ... pricing, and most importantly, dose safety. ...
Cached Medicine Technology:Remedy Informatics CEO, Gary Kennedy, to Speak at Molecular Med TRI-CON 2Remedy Informatics CEO, Gary Kennedy, to Speak at Molecular Med TRI-CON 3ECRI Institute Guides Hospital Decision-Makers in the Purchase of CT Scanning Systems 2ECRI Institute Guides Hospital Decision-Makers in the Purchase of CT Scanning Systems 3
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... December 26, 2014 Parker & ... the best in heating, cooling and plumbing contractor ... hour emergency services in 2014 with regard to ... that Arizona is known for its incredibly hot ... understands the intricacies and details of a wide ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... iFitDress.com, the popular online supplier of wedding dresses and special ... black one-shoulder cocktail dresses . In addition, all these ... discounted prices, up to 70% off. , The ... only. You know, we have thousands of frequent callers in ... items can visit our website for more details. The current ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... YORK, June 2 American Oriental,Bioengineering (NYSE: ... Directors has,authorized a share repurchase program for the ... outstanding common stock., Purchases under this program ... the,open market, privately negotiated transactions, and accelerated stock,repurchase ...
... ... WHO: Valley Forge Medical Center & Hospital, WHERE: 1033 ... ... Medical Center and,Hospital is the first facility on the East Coast to obtain the,Addiction-Free Pain Management ...
... a combination of chemotherapy, biotherapy and radiotherapy prior to ... according to a University of Pittsburgh Cancer Institute (UPCI) ... American Society of Clinical Oncology (ASCO) in Chicago. , ... Center of the University of Pittsburgh Medical Center (UPMC) ...
... Denver, CO June 2, 2008 Results from ... (HBCs) and lost time among employees suffering from multiple ... (DMTs) were presented and announced by Biogen Idec as ... (CMSC) annual meeting in Denver, Colorado, May 28-May 31, ...
... body programs that aid medical ... research and education, ... willed body to science anatomical,donation is currently the fastest-growing trend among ... anatomical,donation can relieve the financial burdens associated with the death of ...
... to researchers at,the American Society of Hypertension (ASH), ... daily may significantly reduce high blood,pressure. This news ... ASH,s Twenty-Third,Annual Scientific Meeting and Exposition in New ... example of rhythmically homogeneous,music!, SonicMood is an ...
Cached Medicine News:Health News:American Oriental Bioengineering Announces US$75 Million Share Repurchase Program 2Health News:Valley Forge Medical Center and Hospital to Become the First Addiction-Free Pain Management Center of Excellence on the East Coast; Will Host Three Day Professional Training Seminar. 2Health News:Valley Forge Medical Center and Hospital to Become the First Addiction-Free Pain Management Center of Excellence on the East Coast; Will Host Three Day Professional Training Seminar. 3Health News:New treatment combination safe for pancreatic cancer patients 2Health News:New data show patients using avonex reported less sick leave and short-term disability costs 2Health News:Online Directory Lists Anatomical Donation Programs in U.S. Offering Free Cremations 2Health News:Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES! 2
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity ...
Handheld Digital Retinal Camera...
Medicine Products: